Navigation Links
In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop
Date:10/7/2008

CAMBRIDGE, Mass., Oct. 7 /PRNewswire/ -- Taligen Therapeutics Inc. today announced that in vivo data on several of the Company's pipeline candidates were presented at the XXII International Complement Workshop in Basel, Switzerland. The data highlighted the candidates' efficacy in several animal models of complement-mediated diseases.

"These highlighted presentations, as well as several in vitro studies presented at the conference, reveal the deep expertise and expanding knowledge base within the complement research community," said Michael Holers, M.D., chief scientific officer of Taligen Therapeutics. "The work, not only from our laboratory but from the laboratories of our collaborators, is unlocking the mechanisms of immunomodulation and enabling Taligen to direct the development of new product candidates and test them in a variety of animal models as a precursor to their clinical development."

"The opportunity to further evaluate Taligen's TT30 compound in our research activities has been invaluable in our characterization of the effects of modulation of the complement system on animal models of human disease," said Steve Tomlinson, Ph.D. and principal investigator of several studies presented at the complement meeting. "Our results in the MRL lupus model in collaboration with Dr. Gary Gilkeson's group now show that targeted complement inhibition using TT30 leads to both local control of inflammation as well as a substantial decrease in the autoimmune response in vivo. No other type of compound has this dual profile of activity. I also believe these CR2-targeted compounds will help future research in the lupus area and hopefully provide therapeutic options for patients."

Key findings from several of the studies testing Taligen's product candidates are highlighted below:

Data support targeting the alternative complement pathway using TT30 as an immunomodulatory compound for treating complement-mediated diseases

In vivo st
'/>"/>

SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
2. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
3. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
4. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
5. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
6. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
(Date:9/1/2015)... ... September 01, 2015 , ... In an ... dental practices across the country are switching from traditional dental impressions to digital ... cosmetic dentist Dr. Sam Saleh of Ora Dentistry Spa, his practice has been ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... is pleased to announce their partnership with Apex Physical Therapy (Apex) ... to continue to provide kind, compassionate, and empathetic care to local residents from ...
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the U.S. has ... and needs. Money for Good 2015, released today by Camber Collective, goes to the ... potential to mobilize up to $22B in new philanthropic giving and shift $25B that’s ...
(Date:9/1/2015)... Minnesota (PRWEB) , ... September 01, 2015 , ... ... health care delivery options, Blue Cross and Blue Shield of Minnesota (Blue Cross) ... in 2016. , Based in San Francisco, Doctor On Demand provides immediate ...
(Date:9/1/2015)... Plainsboro, NJ (PRWEB) , ... September 01, 2015 ... ... up with Cleveland Clinic, ranked a top-five hospital by U.S. News & World ... care for cancer patients. , Editorial and marketing groups within OncLive, which ...
Breaking Medicine News(10 mins):Health News:Article on CAD/CAM Dental Technology Highlights the Advantages of 21st Century Dentistry, Notes Ora Dentistry Spa 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3
... , - Advance directive forms that attempt to ... advance care planning a bad name, Aging with Dignity President says ... 19 Paul Malley, President of the national non-profit organization Aging ... the Department of Veterans Affairs current advance care planning tool, "Your ...
... , , , PARSIPPANY, N.J., ... brand products are proud to announce the launch of the Ounce of ... i ds.com , an interactive site featuring educational activities designed to ... effort to educate children and their parents about everyday and seasonal health and ...
... , , PLANO, ... and Perot Systems Corporation (NYSE: PER ) ( ... where Perot Systems will provide technology and business process services to ... services to be managed by Perot Systems includes claims processing, claims ...
... safely and painlessly, researchers say , WEDNESDAY, Aug. 19 ... may someday offer a painless alternative to hypodermic ... The technique could make flu shots a thing of ... safer and more effective, the researchers said. Their work ...
... LANSING, Mich. Scientists at Michigan State University have ... trigger inflammation in the mammary gland. This ... the risk of breast cancer. Progesterone is a ... normal mammary gland. Progesterone previously has been identified as ...
... of Medicine have destroyed prostate cancer tumors in mice by ... the tubes with a brief zap of a laser. ... treat human prostate cancer tumors in mice, left only a ... "That we could eradicate the tumor mass and not harm ...
Cached Medicine News:Health News:Veterans Deserve Respect, Not Sly Coercion in Advance Care Planning, Says Aging with Dignity President 2Health News:The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 2Health News:The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 3Health News:The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 4Health News:Community Health Plan of Washington Selects Perot Systems for Business Process Solutions 2Health News:Community Health Plan of Washington Selects Perot Systems for Business Process Solutions 3Health News:Patch 'Shots' May Someday Replace Injections 2Health News:MSU scientists: Progesterone leads to inflammation 2Health News:DNA-coated nanotubes help kill tumors without harm to surrounding tissue 2
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: